Hayes Daniel, Raison Claire
Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Expert Rev Mol Diagn. 2015 Feb;15(2):165-9. doi: 10.1586/14737159.2015.991893. Epub 2014 Dec 30.
Interview with Daniel Hayes, by Claire Raison (Commissioning Editor) Daniel F Hayes, M.D. is the Stuart A Padnos Professor of Breast Cancer Research and co-Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center (Ann Arbor, MI, USA). Dr Hayes has extensive experience in clinical and translational breast cancer biomarker research, and in drug development and clinical trials. Around 30 years ago, he led the discovery of the circulating breast tumor biomarker, CA15-3, which started his career into further tumor biomarker work. The main thrust of his work since then has been in clinical trials, tumor biomarkers and trying to integrate the two. Dr Hayes is Chair of the Correlative Sciences Committee of the North American Breast Cancer Group (now called the Breast Cancer Steering Committee), and co-chairs the Expert Panel for Tumor Biomarker Practice Guidelines for the American Society of Clinical Oncology.
克莱尔·雷森（责任编辑）对丹尼尔·海斯的访谈 丹尼尔·F·海斯医学博士是密歇根大学综合癌症中心（美国密歇根州安阿伯）斯图尔特·A·帕德诺斯乳腺癌研究教授兼乳腺肿瘤学项目联合主任。海斯博士在临床和转化乳腺癌生物标志物研究以及药物开发和临床试验方面拥有丰富经验。大约30年前，他领导发现了循环乳腺癌生物标志物CA15-3，这开启了他进一步开展肿瘤生物标志物研究的职业生涯。从那时起，他工作的主要方向一直是临床试验、肿瘤生物标志物以及尝试将两者结合起来。海斯博士是北美乳腺癌研究组（现称为乳腺癌指导委员会）相关科学委员会主席，也是美国临床肿瘤学会肿瘤生物标志物实践指南专家小组的联合主席。
